Device Debut: Medtronic Pulls Riptide Into Growing Stroke Offering
Riptide complements Medtronic's Solitaire stent retriever revascularization device for the treatment of acute ischemic stroke. The company began rolling out Riptide at this year's International Stroke Conference, which also featured the presentation of important clinical data supporting aspiration as a first-line therapy for stroke.
You may also be interested in...
The medtech giant reported revenue of $7.5bn in the quarter that ended on 26 July, up 3.5% year-over-year basis, led by 12.5% growth in revenues from emerging markets. Medtronic’s fastest-growing business is its brain therapies unit, which reported 11.4% growth in the quarter.
Results of the COMPASS trial showed that Penumbra's aspiration system is non-inferior to stent-retrievers as a first-line therapy to treat acute ischemic stroke. COMPASS was one of several important device trials featured at the presented at the International Stroke Conference held in Los Angeles.
The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.